Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

288 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hydrolyzed infant formula and early β-cell autoimmunity: a randomized clinical trial.
Knip M, Åkerblom HK, Becker D, Dosch HM, Dupre J, Fraser W, Howard N, Ilonen J, Krischer JP, Kordonouri O, Lawson ML, Palmer JP, Savilahti E, Vaarala O, Virtanen SM; TRIGR Study Group. Knip M, et al. Among authors: palmer jp. JAMA. 2014 Jun 11;311(22):2279-87. doi: 10.1001/jama.2014.5610. JAMA. 2014. PMID: 24915259 Free PMC article. Clinical Trial.
Effect of Hydrolyzed Infant Formula vs Conventional Formula on Risk of Type 1 Diabetes: The TRIGR Randomized Clinical Trial.
Writing Group for the TRIGR Study Group; Knip M, Åkerblom HK, Al Taji E, Becker D, Bruining J, Castano L, Danne T, de Beaufort C, Dosch HM, Dupre J, Fraser WD, Howard N, Ilonen J, Konrad D, Kordonouri O, Krischer JP, Lawson ML, Ludvigsson J, Madacsy L, Mahon JL, Ormisson A, Palmer JP, Pozzilli P, Savilahti E, Serrano-Rios M, Songini M, Taback S, Vaarala O, White NH, Virtanen SM, Wasikowa R. Writing Group for the TRIGR Study Group, et al. Among authors: palmer jp. JAMA. 2018 Jan 2;319(1):38-48. doi: 10.1001/jama.2017.19826. JAMA. 2018. PMID: 29297078 Free PMC article. Clinical Trial.
Role of insulin resistance in predicting progression to type 1 diabetes.
Xu P, Cuthbertson D, Greenbaum C, Palmer JP, Krischer JP; Diabetes Prevention Trial-Type 1 Study Group. Xu P, et al. Among authors: palmer jp. Diabetes Care. 2007 Sep;30(9):2314-20. doi: 10.2337/dc06-2389. Epub 2007 May 29. Diabetes Care. 2007. PMID: 17536068
First test effect in intravenous glucose tolerance testing.
Ismail HM, White KS, Krischer JP, Chase HP, Cuthbertson D, Palmer JP; DPT-1 Study Group. Ismail HM, et al. Among authors: palmer jp. Pediatr Diabetes. 2015 Mar;16(2):129-37. doi: 10.1111/pedi.12064. Epub 2013 Aug 15. Pediatr Diabetes. 2015. PMID: 23944770 Free PMC article.
Validation of the Diabetes Prevention Trial-Type 1 Risk Score in the TrialNet Natural History Study.
Sosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, Greenbaum CJ, Rafkin LE, Cowie C, Cuthbertson D, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. Sosenko JM, et al. Among authors: palmer jp. Diabetes Care. 2011 Aug;34(8):1785-7. doi: 10.2337/dc11-0641. Epub 2011 Jun 16. Diabetes Care. 2011. PMID: 21680724 Free PMC article.
Multiple factors affect the loss of measurable C-peptide over 6 years in newly diagnosed 15- to 35-year-old diabetic subjects.
Jensen RA, Gilliam LK, Törn C, Landin-Olsson M, Karlsson FA, Palmer JP, Kockum I, Akesson K, Lernmark B, Lynch K, Breslow N, Lernmark A; Diabetes Incidence Study in Sweden (DISS) group. Jensen RA, et al. Among authors: palmer jp. J Diabetes Complications. 2007 Jul-Aug;21(4):205-13. doi: 10.1016/j.jdiacomp.2006.01.004. J Diabetes Complications. 2007. PMID: 17616349
288 results